Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Jan 11;12(1):e0169152.
doi: 10.1371/journal.pone.0169152. eCollection 2017.

Subfoveal Choroidal Thickness in Central Serous Chorioretinopathy: A Meta-Analysis

Guohai Chen  1 , Radouil Tzekov  2   3 , Wensheng Li  4 , Fangzheng Jiang  1 , Sihong Mao  1 , Yuhua Tong  1
Affiliations
Meta-Analysis

Subfoveal Choroidal Thickness in Central Serous Chorioretinopathy: A Meta-Analysis

Guohai Chen et al. PLoS One. .

Abstract

Purpose: To evaluate the relationship between subfoveal choroidal thickness (SFCT) and eyes with central serous chorioretinopathy (CSC) versus fellow or control eyes.

Methods: We performed a meta-analysis using databases including PubMed, Embase and ISI Web of Science to find relevant studies. Weighted mean difference (WMD) was calculated for the SFCT in CSC eyes, the unaffected fellow eyes and normal controls.

Results: Twelve studies were selected for this meta-analysis, including 1108 eyes (397 CSC eyes, 228 unaffected fellow eyes and 483 eyes of normal controls). The meta-analysis clearly demonstrated that the subfoveal choiroid of eyes with a clinical presentation of CSC was thickened compared to unaffected fellow eyes (WMD = 52.81, 95% confidence interval (CI), 39.13-66.49, P<0.00001) and was thickened compared to control eyes (WMD = 145.03, 95%CI, 121.33-168.73, P<0.00001). The mean SFCT measurement of the unaffected fellow eyes showed also significantly increased choroidal thickness compared to that of normal control eyes (WMD = 77.20, 95% CI, 44.98-109.42, P<0.00001). Similar results were obtained in a sub-analysis based on the same instrument.

Conclusion: It is demonstrated that SFCT is significantly increased in eyes with clinical manifestation of CSC, and in the clinically non-manifested fellow eyes. These results support the hypothesis that CSC is a bilateral disorder with an initial unilateral clinical presentation.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Flow diagram describing selection of studies about association between choroidal thickness and CSC status.
Fig 2
Fig 2. Random-effects model evaluating the association between subfoveal choroidal thickness in CSC eyes and normal control eyes.
CSC, central serous chorioretinopathy; SD, standard deviation; IV, inverse variance; CI, confidence interval.
Fig 3
Fig 3. Random-effects model evaluating the association between subfoveal choroidal thickness in unaffected fellow eyes and normal control eyes.
SD, standard deviation; IV, inverse variance; CI, confidence interval.
Fig 4
Fig 4. Meta-analysis of the association between subfoveal choroidal thickness in CSC eyes and unaffected fellow eyes.
CSC, central serous chorioretinopathy; SD, standard deviation; IV, inverse variance; CI: confidence interval.
Fig 5
Fig 5. Sub-analysis based on measurement of subfoveal choroidal thickness using Spectralis SD-OCT.
(A) CSC eyes vs. normal controls, (B) Unaffected fellow eyes vs. normal controls, and (C) CSC eyes vs. unaffected fellow eyes. CSC, central serous chorioretinopathy; SD, standard deviation; IV, inverse variance; CI, confidence interval.
Fig 6
Fig 6. Subfoveal choroidal thickness in control eyes and in eyes with a clinical presentation of CSC determined by using Spectralis SD-OCT.
Filled circles represent mean values of subfoveal choroidal thickness (SFCT) in eyes with clinical presentation of CSC, while filled squares represent mean valued of SFCT in control eyes. Error bars indicate standard deviations. Two enlarged symbols in the right end of the figure represent the average SFCT value for each group. The dotted line represents the mid point between the lower end of the standard deviation of CSC-affected eyes and the upper end of the standard deviation of the control eyes. CSC, central serous chorioretinopathy.
See this image and copyright information in PMC

References

    1. Nicholson B, Noble J, Forooghian F, Meyerle C. Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol. 2013;58(2):103–26. 10.1016/j.survophthal.2012.07.004 - DOI - PMC - PubMed
    1. Daruich A, Matet A, Dirani A, Bousquet E, Zhao M, Farman N, et al. Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis. Prog Retin Eye Res. 2015;48:82–118. 10.1016/j.preteyeres.2015.05.003 - DOI - PubMed
    1. Spaide RF, Campeas L, Haas A, Yannuzzi LA, Fisher YL, Guyer DR, et al. Central serous chorioretinopathy in younger and older adults. Ophthalmology. 1996;103(12):2070–80. - PubMed
    1. Liew G, Quin G, Gillies M, Fraser-Bell S. Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Experiment Ophthalmol. 2013;41(2):201–14. 10.1111/j.1442-9071.2012.02848.x - DOI - PubMed
    1. Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980–2002. Ophthalmology. 2008;115(1):169–73. 10.1016/j.ophtha.2007.02.032 - DOI - PubMed

Publication types